Relationship Between the Eosinophil/Monocyte Ratio and Prognosis in Decompensated Heart Failure: A Retrospective Study

References

• Zhang Z, Cao L, Chen R, et al. Electronic healthcare records and external outcome data for hospitalized patients with heart failure. Sci Data. 2021;8:46. doi:10.1038/s41597-021-00835-9
   PubMed Web of Science ®Google Scholar
• Pons F, Lupon J, Urrutia A, et al. Mortality and cause of death in patients with heart failure: findings at a specialist multidisciplinary heart failure unit. Rev Esp Cardiol. 2010;63:303–314. doi:10.1016/S0300-8932(10)70089-0
   PubMed Web of Science ®Google Scholar
• Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11:329–337.
   PubMedGoogle Scholar
• Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation. 2008;118:625–631. doi:10.1161/CIRCULATIONAHA.107.759191
   PubMed Web of Science ®Google Scholar
• Hage C, Michaelsson E, Linde C, et al. Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: a holistic proteomic approach. Circ Cardiovasc Genet. 2017;10:e001633. doi:10.1161/CIRCGENETICS.116.001633
   PubMedGoogle Scholar
• Seguela PE, Iriart X, Acar P, Montaudon M, Roudaut R, Thambo JB. Eosinophilic cardiac disease: molecular, clinical and imaging aspects. Arch Cardiovasc Dis. 2015;108:258–268. doi:10.1016/j.acvd.2015.01.006
   PubMed Web of Science ®Google Scholar
• Yu S, Luo Y, Zhang T, et al. Eosinophil-to-monocyte ratio is a potential biomarker in the prediction of functional outcome among patients with acute ischemic stroke. BMC Neurosci. 2021;22:8. doi:10.1186/s12868-021-00610-x
   PubMed Web of Science ®Google Scholar
• Chen Y, Ren J, Yang N, et al. Eosinophil-to-monocyte ratio is a potential predictor of prognosis in acute ischemic stroke patients after intravenous thrombolysis. Clin Interv Aging. 2021;16:853–862. doi:10.2147/CIA.S309923
   PubMed Web of Science ®Google Scholar
• Deng X, Wang X, Shen L, et al. Association of eosinophil-to-monocyte ratio with 1-month and long-term all-cause mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Thorac Dis. 2018;10:5449–5458. doi:10.21037/jtd.2018.09.27
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
   PubMed Web of Science ®Google Scholar
• Liu T, Song D, Dong J, et al. Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure. Front Physiol. 2017;8:238. doi:10.3389/fphys.2017.00238
   PubMed Web of Science ®Google Scholar
• Bracamonte-Baran W, Cihakova D. Cardiac autoimmunity: myocarditis. Adv Exp Med Biol. 2017;1003:187–221.
   PubMed Web of Science ®Google Scholar
• Iacobazzi D, Suleiman MS, Ghorbel M, George SJ, Caputo M, Tulloh RM. Cellular and molecular basis of RV hypertrophy in congenital heart disease. Heart. 2016;102:12–17. doi:10.1136/heartjnl-2015-308348
   PubMed Web of Science ®Google Scholar
• Mouton AJ, Rivera OJ, Lindsey ML. Myocardial infarction remodeling that progresses to heart failure: a signaling misunderstanding. Am J Physiol Heart Circ Physiol. 2018;315:H71–H79. doi:10.1152/ajpheart.00131.2018
   PubMed Web of Science ®Google Scholar
• Strassheim D, Dempsey EC, Gerasimovskaya E, Stenmark K, Karoor V. Role of inflammatory cell subtypes in heart failure. J Immunol Res. 2019;2019:2164017. doi:10.1155/2019/2164017
   PubMed Web of Science ®Google Scholar
• Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206. doi:10.1016/0735-1097(95)00589-7
   PubMed Web of Science ®Google Scholar
• Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med. 2005;37:74–85. doi:10.1080/07853890510007232
   PubMed Web of Science ®Google Scholar
• Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491. doi:10.1161/01.CIR.0000057810.48709.F6
   PubMed Web of Science ®Google Scholar
• St-Pierre AC, Cantin B, Bergeron J, et al. Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis. 2005;182:315–321. doi:10.1016/j.atherosclerosis.2005.02.009
   PubMed Web of Science ®Google Scholar
• Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E, Garcia MJ. Anti-inflammatory therapy for cardiovascular disease. Ann Transl Med. 2019;7:147. doi:10.21037/atm.2019.02.34
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847. doi:10.1056/NEJMoa2021372
   PubMed Web of Science ®Google Scholar
• Peng H, Sarwar Z, Yang XP, et al. Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction. Hypertension. 2015;66:582–589. doi:10.1161/HYPERTENSIONAHA.115.05627
   PubMed Web of Science ®Google Scholar
• Liu J, Yang C, Liu T, et al. Eosinophils improve cardiac function after myocardial infarction. Nat Commun. 2020;11:6396. doi:10.1038/s41467-020-19297-5
   PubMed Web of Science ®Google Scholar
• Meisel SR, Pauzner H, Shechter M, Zeidan Z, David D. Peripheral monocytosis following acute myocardial infarction: incidence and its possible role as a bedside marker of the extent of cardiac injury. Cardiology. 1998;90:52–57. doi:10.1159/000006817
   PubMed Web of Science ®Google Scholar
• Wang KT, Liu YY, Sung KT, et al. Circulating monocyte count as a surrogate marker for ventricular-arterial remodeling and incident heart failure with preserved ejection fraction. Diagnostics. 2020;10(5):287. doi:10.3390/diagnostics10050287
   Web of Science ®Google Scholar
• Charach G, Rogowski O, Karniel E, Charach L, Grosskopf I, Novikov I. Monocytes may be favorable biomarker and predictor of long-term outcome in patients with chronic heart failure: a cohort study. Medicine. 2019;98:e17108. doi:10.1097/MD.0000000000017108
   PubMed Web of Science ®Google Scholar
• Mongirdiene A, Laukaitiene J, Skipskis V, Kursvietiene L, Liobikas J. Platelet activity and its correlation with inflammation and cell count readings in chronic heart failure patients with reduced ejection fraction. Medicina. 2021;57:176.
   PubMedGoogle Scholar
• Maekawa Y, Anzai T, Yoshikawa T, et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol. 2002;39:241–246. doi:10.1016/S0735-1097(01)01721-1
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti TNFTACHFI. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–3140.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044–1047. doi:10.1161/01.CIR.103.8.1044
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–1602. doi:10.1161/01.CIR.0000124490.27666.B2
   PubMed Web of Science ®Google Scholar
• Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. Ann Transl Med. 2018;6:121. doi:10.21037/atm.2018.02.12
   PubMed Web of Science ®Google Scholar